Last reviewed · How we verify

Postoperative ileus — Treatment Landscape & Competitive Intelligence

Postoperative ileus (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Postoperative ileus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Entereg ALVIMOPAN Cubist Pharms Opioid Antagonist µ-opioid receptor 2008-01-01
Entereg Entereg Hartford Hospital Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Cubist Pharms · 1 drug in Postoperative ileus
  2. Hartford Hospital · 1 drug in Postoperative ileus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Postoperative ileus:

Cite this brief

Drug Landscape (2026). Postoperative ileus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postoperative-ileus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing